Sinopia Biosciences

Sinopia Biosciences is a biotechnology company leveraging a multi-omics powered AI/ML drug discovery platform to identify and advance novel therapeutics. Sinopia's platform deploys high-throughput screening, omics profiling, and advanced algorithms and has successfully identified several therapeutic opportunities. Using this approach, Sinopia has discovered a first-in-class small molecule for Parkinson's disease and levodopa-induced dyskinesia (PD/LID). Sinopia is advancing its PD/LID program through IND-enabling studies with financial support from The Michael J. Fox Foundation and the NIH and plans to initiate its clinical development in Q2, 2024. Sinopia is also applying its data-driven approach in discovery for oncology and rare diseases. The Company has been supported with $14M in grant funding from the NIH and The Michael J. Fox Foundation and is currently seeking partnering and/or venture and strategic financing to advance its clinical candidate, pipeline, and platform.